US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,375.27

+19.551.44%

Number of Gainers:17

Number of Losers:2

Number of Flat:1

PE:- -

High:1,386.07

Open:1,359.33

Low:1,359.33

Close:1,355.71

Loading ...

Here's Why Astrazeneca (AZN) is a Strong Value Stock

Pfizer Shares Fall 1.8% After Q1 Revenue Miss

THOMSON REUTERS

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

US FDA chief says firings won't hinder agency's target dates for drug reviews

BRIEF-FDA Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml To Be Discontinued Due To Business Decision - Website

FDA: Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml to Be Discontinued Due to Business Decision - Website

THOMSON REUTERS

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

ACCESS Newswire

BRIEF-Pfizer - Expects About $1.6 Bln One-Time Costs To Achieve Additional Savings To Be Incurred Through 2027 - SEC Filing

BRIEF-Novavax Appoints Charles Newton To Board Of Directors

Pfizer Inc - Expects $500 Million Savings From R&D Simplification by 2026 - SEC Filing

THOMSON REUTERS

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

Novavax Appoints Charles Newton to Board of Directors

THOMSON REUTERS

Press Release: Novavax Appoints Charles Newton to Board of Directors

Deutsche Bank Remains a Buy on BioNTech SE (BNTX)

UBS Remains a Buy on AstraZeneca (AZN)

If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

BRIEF-Pfizer Says Focused On Mitigating Opportunities In Near & Longer Term Regarding Potential Future Changes In Trade And Tariff

BRIEF-Pfizer Reports First-Quarter 2025 Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1375.2667,"timestamp":1746215999999,"preClose":1355.7122,"halted":0,"volume":90281388,"delay":0,"changeRate":0.014424,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":19.554565,"latestTime":"05-02 16:00:00 EDT","open":1359.3263,"high":1386.07,"low":1359.3263,"amount":4683518595.783152,"amplitude":0.019727,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.644075,"peRate":21.713814,"turnoverRate":0.005819,"increases":17,"decrements":2,"flats":1,"marketCap":1136531230970,"floatMarketCap":1116501984572.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1386.07,"amplitude":0.019727,"preClose":1355.7122,"low":1359.3263,"pbRate":"3.644075","latestPrice":1375.2667,"volume":90281388,"delay":0,"open":1359.3263,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1341.1263,"twentyDayClose":1401.546,"sixtyDayClose":1373.9138,"secType":"PLATE","market":"US","turnoverRate":0.005819,"peRate":21.713814,"marketCap":1136531230970,"floatMarketCap":1116501984572.5,"timestamp":1746215999999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":17,"down":2,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531765632","title":"Here's Why Astrazeneca (AZN) is a Strong Value Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765632","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765632?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:40","pubTimestamp":1745934006,"startTime":"0","endTime":"0","summary":"Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Why Investors Should Pay Attention to This Value Stock. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.Many value investors pay close attention to a company's earnings as well. For AZN, two analysts revised their earnings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-astrazeneca-azn-strong-134006344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0320765992.SGD","BK4007","LU0109394709.USD","LU2236285917.USD","LU1829250122.USD","LU2417539215.USD","BK4588","LU0889565916.HKD","AZN","BK4568","LU2462157665.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2531342737","title":"Pfizer Shares Fall 1.8% After Q1 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2531342737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531342737?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:32","pubTimestamp":1745933557,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R71QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4592","IE00BLSP4239.USD","SG9999013999.USD","LU0234572021.USD","SG9999011175.SGD","IE00B19Z3581.USD","BK4588","LU0456855351.SGD","LU0306806265.USD","BK4534","LU1894683264.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU0321505439.SGD","BK4581","IE0002270589.USD","LU0225284248.USD","IE00B19Z3B42.SGD","BK4550","LU0985481810.HKD","PFE","SG9999001176.USD","IE00BBT3K403.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU0170899867.USD","LU1066051498.USD","LU0058720904.USD","BK4599","BK4585","LU1023059063.AUD","SG9999001176.SGD","IE00BLSP4452.SGD","LU0289739699.SGD","SG9999002224.SGD","SG9999002232.USD","LU0306807586.USD","BK4568","LU0868494617.USD","BK4533","LU1894683348.USD","LU0321505868.SGD","LU1883839398.USD","BK4007","LU1057294990.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2531898734","title":"AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531898734","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531898734?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:09","pubTimestamp":1745932140,"startTime":"0","endTime":"0","summary":"1309 GMT - AstraZeneca's revenue miss in oncology segment should concern investors but its long-term story seems intact, Barclays analysts say in a note. The British pharma giant posted mixed 1Q results as some of its oncology and rare disease drugs fell short of company-compiled sales consensus, the analysts say. \"While we believe investors would question the oncology misses, important catalyst readouts planned for later this year and AstraZeneca being less susceptible to the ever-emerging tariff situation in the U.S., we see AstraZeneca as best positioned in our coverage,\" they say. Shares are down 0.3% at 104.90 pounds. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU1829250122.USD","LU0889565916.HKD","LU2456880835.USD","LU2462157665.USD","LU0320765992.SGD","BK4568","BK4585","BK4588","LU2417539215.USD","LU2236285917.USD","BK4007","AZN"],"gpt_icon":0},{"id":"2531754656","title":"Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information","url":"https://stock-news.laohu8.com/highlight/detail?id=2531754656","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531754656?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:05","pubTimestamp":1745931900,"startTime":"0","endTime":"0","summary":"Collaboration brings together FreeStyle Libre Systems, the world's leading continuous glucose monitoring technology 1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations. Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows. ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott , the global leader in continuous glucose monitoring  biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers.Now, more than 575,000 U.S. healthcare providers serving 2802 million patients will have access to critical glucose data in their patient","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbott-integrates-libres-data-epics-130500583.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbott-integrates-libres-data-epics-130500583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU1989763690.USD","LU2237957811.SGD","SG9999004303.SGD","BK4137","BK4592","ABT","LU0122379950.USD","IE0002141913.USD","IE00B4R5TH58.HKD","LU1721429741.USD","BK4533","BK4588","BK4504","SG9999002224.SGD","LU0170899867.USD","BK4134","BK4581","IE0009355771.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU2089984988.USD","IE00BFTCPJ56.SGD","BK4585","HCSG","SGXZ23171101.USD","IE00BJJMRZ35.SGD","LU1721429402.USD","LU1057294990.SGD","LU0868494617.USD","LU1691799644.USD","LU1989763427.SGD","LU1061106388.HKD","LU1023059063.AUD","LU2237957902.USD","BK4566","LU0234572021.USD","SG9999002232.USD","III","BK4082","IE00B2B36J28.USD","LU2112291526.USD","LU1914381329.SGD","LU0266013472.USD","LU2133065610.SGD"],"gpt_icon":0},{"id":"2531828736","title":"US FDA chief says firings won't hinder agency's target dates for drug reviews","url":"https://stock-news.laohu8.com/highlight/detail?id=2531828736","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531828736?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:42","pubTimestamp":1745930556,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration will meet its targets for completing reviews of new drugs despite mass firings at the agency under the Trump administration, its chief said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R719F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4568","BK4585","BK4139","BK4588"],"gpt_icon":1},{"id":"2531354597","title":"BRIEF-FDA Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml To  Be Discontinued Due To Business Decision - Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2531354597","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531354597?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:38","pubTimestamp":1745930329,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml To  Be Discontinued Due To Business Decision - WebsiteApril 29  - Pfizer Inc PFE.N:FDA: HEPARIN SODIUM, INJECTION, 5000 [USP'U]/1 ML TO  BE DISCONTINUED DUE TO BUSINESS DECISION - WEBSITESource text: [ID:]Further company coverage: PFE.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R7234:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011175.SGD","LU0306807586.USD","IE00B19Z3581.USD","LU1057294990.SGD","LU1894683348.USD","BK4585","BK4592","BK4007","IE000M9KFDE8.USD","SG9999002224.SGD","BK4568","IE00BLSP4452.SGD","LU0058720904.USD","LU0122379950.USD","BK4581","LU0225284248.USD","LU0985481810.HKD","BK4550","BK4534","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1883839398.USD","LU1066051498.USD","LU0321505868.SGD","IE00BBT3K403.USD","SG9999001176.USD","LU0234572021.USD","SG9999001176.SGD","LU0306806265.USD","SG9999002232.USD","LU1894683264.USD","BK4599","IE0002270589.USD","SG9999013999.USD","IE00BLSP4239.USD","LU0170899867.USD","LU0225771236.USD","LU1023059063.AUD","SG9999003800.SGD","BK4533","LU0289739699.SGD","SGXZ57979304.SGD","LU0868494617.USD","BK4588","PFE","LU0456855351.SGD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2531359477","title":"FDA: Heparin Sodium, Injection, 5000 [Usp'u]/1 Ml to  Be Discontinued Due to Business Decision - Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2531359477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531359477?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:38","pubTimestamp":1745930289,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R7234:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999011175.SGD","LU0306807586.USD","IE00B19Z3581.USD","LU1057294990.SGD","LU1894683348.USD","BK4585","BK4592","BK4007","IE000M9KFDE8.USD","SG9999002224.SGD","BK4568","IE00BLSP4452.SGD","LU0058720904.USD","LU0122379950.USD","BK4581","LU0225284248.USD","LU0985481810.HKD","BK4550","BK4534","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1883839398.USD","LU1066051498.USD","LU0321505868.SGD","IE00BBT3K403.USD","SG9999001176.USD","LU0234572021.USD","SG9999001176.SGD","LU0306806265.USD","SG9999002232.USD","LU1894683264.USD","BK4599","IE0002270589.USD","SG9999013999.USD","IE00BLSP4239.USD","LU0170899867.USD","LU0225771236.USD","LU1023059063.AUD","SG9999003800.SGD","BK4533","LU0289739699.SGD","SGXZ57979304.SGD","LU0868494617.USD","BK4588","PFE","LU0456855351.SGD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2531775351","title":"Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2531775351","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531775351?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:35","pubTimestamp":1745930100,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / April 29, 2025 / Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu - an online mapping tool that visualizes granular data related to the HIV epidemic in the United States.The tool was designed to help increase awareness and understanding of the impact of HIV across the U.S., especially in the South.AIDSVu analyses have revealed that although new HIV diagnoses have been declining throughout the country from 2008 to 2022, this progress has been uneven across regions. For example, the U.S. South saw only a 17% decrease in new HIV diagnoses during this period compared to a 43% decrease in the Northeast.\"Data is power,\" he says. \"Whether you are a mathematical person or a visual person, you can come and look and we can have a common understanding of what the HIV epidemic looks like in our city, in our ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-aidsvu-online-mapping-123500779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","BK4211","LU0058720904.USD","IE0002270589.USD","IE00B19Z3581.USD","LU0109394709.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","BK4550","BK4588","LU0234570918.USD","LU1430594728.SGD","LU1066053197.SGD","LU2468319806.SGD","LU0320765992.SGD","BK4583","BK4585","LU2087621335.USD","LU1571399168.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","IE00BSNM7G36.USD","LU1585245621.USD","BK4566","LU1839511570.USD","LU0889565916.HKD","BK4139","BK4578","BK4532","LU1066051498.USD","GILD","IE00BKVL7J92.USD","BK4568","LU2089984988.USD","UBCP"],"gpt_icon":0},{"id":"2531833735","title":"BRIEF-Pfizer - Expects About $1.6 Bln One-Time Costs To Achieve Additional Savings To Be Incurred Through 2027 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2531833735","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531833735?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:29","pubTimestamp":1745929793,"startTime":"0","endTime":"0","summary":"BRIEF-Pfizer - Expects About $1.6 Bln One-Time Costs To Achieve Additional Savings To Be Incurred Through 2027 - SEC FilingApril 29  - Pfizer Inc PFE.N:PFIZER - EXPECTS ABOUT $1.6 BILLION ONE-TIME COSTS TO ACHIEVE ADDITIONAL SAVINGS TO BE INCURRED THROUGH 2027 - SEC FILINGPFIZER INC - EXPECTS $500 MILLION SAVINGS FROM RESEARCH AND DEVELOPMENT SIMPLIFICATION BY 2026 - SEC FILINGPFIZER INC - EXPECTS $600 MILLION ONE-TIME COSTS THROUGH 2026 FROM RESEARCH AND DEVELOPMENT SIMPLIFICATION  - SEC FILINGSource text: [ID:n0000078003-25-000111]Further company coverage: PFE.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R714T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","LU0306807586.USD","BK4550","IE0002270589.USD","SG9999001176.USD","LU1894683264.USD","BK4599","LU1057294990.SGD","BK4568","SG9999013999.USD","BK4534","LU0170899867.USD","LU0122379950.USD","LU0225284248.USD","LU0306806265.USD","SG9999011175.SGD","PFE","BK4585","IE00B19Z3B42.SGD","LU0985481810.HKD","LU0058720904.USD","LU0321505439.SGD","IE00B19Z3581.USD","BK4007","LU0321505868.SGD","LU1066053197.SGD","SG9999003800.SGD","BK4592","LU1883839398.USD","LU0289739699.SGD","SG9999002224.SGD","IE00BLSP4452.SGD","LU0234572021.USD","BK4533","IE00BLSP4239.USD","LU0456855351.SGD","BK4588","LU1023059063.AUD","LU0868494617.USD","SG9999001176.SGD","SGXZ57979304.SGD","SG9999002232.USD","LU1066051498.USD","LU0225771236.USD","LU1894683348.USD","IE000M9KFDE8.USD","BK4581"],"gpt_icon":1},{"id":"2531738424","title":"BRIEF-Novavax Appoints Charles Newton To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531738424","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531738424?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:18","pubTimestamp":1745929096,"startTime":"0","endTime":"0","summary":"BRIEF-Novavax Appoints Charles Newton To Board Of DirectorsNovavax Inc NVAX.O:NOVAVAX APPOINTS CHARLES NEWTON TO BOARD OF DIRECTORSSource text: [ID:]Further company coverage: NVAX.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R71PX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4547","BK4585","BK4568","NVAX","BK4588"],"gpt_icon":0},{"id":"2531738824","title":"Pfizer Inc - Expects $500 Million Savings From R&D Simplification by 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2531738824","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531738824?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:07","pubTimestamp":1745928429,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R714T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999003800.SGD","SG9999001176.SGD","LU0225771236.USD","LU0058720904.USD","LU1023059063.AUD","BK4533","LU0985481810.HKD","PFE","SG9999002232.USD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4007","BK4550","BK4588","LU0321505868.SGD","LU0306807586.USD","IE00BBT3K403.USD","LU0321505439.SGD","LU0234572021.USD","SG9999001176.USD","BK4585","BK4592","BK4568","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","SGXZ57979304.SGD","SG9999013999.USD","LU0868494617.USD","LU1883839398.USD","LU1894683264.USD","BK4534","IE000M9KFDE8.USD","BK4581","LU0456855351.SGD","BK4599","SG9999011175.SGD","LU0170899867.USD","LU0289739699.SGD","IE00B19Z3581.USD","LU0225284248.USD","LU0306806265.USD","LU1057294990.SGD","IE0002270589.USD","LU1894683348.USD"],"gpt_icon":0},{"id":"2531733506","title":"INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531733506","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531733506?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:05","pubTimestamp":1745928300,"startTime":"0","endTime":"0","summary":"PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO , a biotechnology company focused on developing and commercializing DNA medicines tohelp treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inovio-report-first-quarter-2025-120500615.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inovio-report-first-quarter-2025-120500615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","INO","BK4583","BK4139"],"gpt_icon":0},{"id":"2531787407","title":"Novavax Appoints Charles Newton to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531787407","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531787407?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928017,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA9PTKW5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4547","NVAX","BK4568","BK4139","BK4585"],"gpt_icon":0},{"id":"2531780352","title":"Press Release: Novavax Appoints Charles Newton to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531780352","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531780352?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc.  today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors.\"Charles brings a wealth of expertise across corporate finance and capital markets to Novavax,\" said John C. Jacobs, President and Chief Executive Officer, Novavax. \"The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corporate growth strategy focused on forging strategic partnerships for our R&D assets and our Matrix-M adjuvant.\". Statements herein other than statements of historical fact, including statements relating to the Company's corporate growth strategy, the composition of its Board of Directors, and expectations regarding its clinical pipeline through strategic collaborations, are forward-looking statements. Novavax cautions that these","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","NVAX","BK4022","BNTX","BK4568","BK4139","BK4551","BK4585","BK4232","BK4535","BK4588","R","BK4548"],"gpt_icon":1},{"id":"2531871227","title":"Deutsche Bank  Remains a Buy on BioNTech SE (BNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531871227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531871227?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:57","pubTimestamp":1745927825,"startTime":"0","endTime":"0","summary":"In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/deutsche-bank-remains-a-buy-on-biontech-se-bntx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/deutsche-bank-remains-a-buy-on-biontech-se-bntx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DB","BK4548","BK4535","BK4551","BK4552","BK4568","BK4585","BK4588","BK4118","BK4566","BNTX","BK4139"],"gpt_icon":0},{"id":"2531787454","title":"UBS Remains a Buy on AstraZeneca (AZN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531787454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531787454?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:56","pubTimestamp":1745927819,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £142.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-buy-on-astrazeneca-azn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-buy-on-astrazeneca-azn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2417539215.USD","BK4585","LU1829250122.USD","LU0109394709.USD","BK4007","AZN","BK4588","LU2462157665.USD","LU0320765992.SGD","BK4568","LU2236285917.USD","LU2456880835.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2531822717","title":"If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2531822717","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531822717?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:45","pubTimestamp":1745927100,"startTime":"0","endTime":"0","summary":"Things were going great, right until the point when they weren't.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/29/if-youd-invested-10000-in-pfizer-stock-10-years-ag/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00BLSP4452.SGD","BK4551","SG9999003800.SGD","IE000M9KFDE8.USD","BK4592","BK4535","LU0225771236.USD","LU1023059063.AUD","LU1066051498.USD","BK4139","LU0122379950.USD","BK4581","LU0456855351.SGD","BK4588","LU0058720904.USD","BK4599","IE0002270589.USD","LU0306806265.USD","PFE","LU0321505439.SGD","BK4568","LU1057294990.SGD","LU0868494617.USD","IE00B19Z3B42.SGD","BK4548","SG9999011175.SGD","IE00B19Z3581.USD","BK4585","LU1894683348.USD","LU0170899867.USD","LU1883839398.USD","BNTX","LU0985481810.HKD","SG9999001176.USD","SGXZ57979304.SGD","LU1894683264.USD","BK4550","SG9999002232.USD","LU0234572021.USD","LU0321505868.SGD","IE00BBT3K403.USD","SG9999002224.SGD","BK4533","LU0306807586.USD","LU0289739699.SGD","SG9999001176.SGD","BK4007","BK4534","IE00BLSP4239.USD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2531782612","title":"Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531782612","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531782612?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:30","pubTimestamp":1745926200,"startTime":"0","endTime":"0","summary":"“We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the retina community,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “Ocugen remains on track to deliver on our commitment to file three Biologics License Applications/Marketing Authorization Applications  in the next three years—potentially addressing significant unmet medical need for large patient populations through our gene-agnostic approach.”Ocugen’s presence in Utah kicks off with the Company Showcase at Eyecelerator, presented by Dr. Huma Qamar, Chief Medical Officer at Ocugen, and continues through presentations and thought leadership engagement at ARVO.Session: Retina—Gene Therapy and Novel Mechanisms of Action ShowcaseLocation: Grand Hyatt Deer Valley,Strawberry Ballroom, Park City, UTDate: Friday, May 2, 2025Time: 2:06 p.m. MDTPresenter: Dr. Huma Qamar. Safety and Effic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-present-modifier-gene-therapy-113000315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OCGN","BK4568","BK4563","BK4139"],"gpt_icon":0},{"id":"2531893307","title":"BRIEF-Pfizer Says Focused On Mitigating Opportunities In Near & Longer Term Regarding Potential Future Changes In Trade And Tariff","url":"https://stock-news.laohu8.com/highlight/detail?id=2531893307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531893307?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:12","pubTimestamp":1745925170,"startTime":"0","endTime":"0","summary":"BRIEF-Pfizer Says Focused On Mitigating Opportunities In Near & Longer Term Regarding Potential Future Changes In Trade And Tariff April 29  - Pfizer Inc PFE.N:PFIZER: FOCUSED ON MITIGATING OPPORTUNITIES IN NEAR & LONGER TERM REGARDING POTENTIAL FUTURE CHANGES IN TRADE AND TARIFF POLICIES - PREPARED REMARKSPFIZER - ASSESSING ACTIONS INCLUDING POTENTIAL PRODUCTION OF CERTAIN API & PRODUCTS IN U.S. - PREPARED REMARKSPFIZER - ASSESSING ACTIONS LIKE MANAGEMENT OF CURRENT INVENTORY LEVELS IN SOME JURISDICTIONS, LEVERAGING DOMESTIC MANUFACTURING FOOTPRINTPFIZER:IN TOTAL, EXPECT ABOUT $7.7 BILLION IN SAVINGS BY THE END OF 2027 TO DRIVE OPERATING EFFICIENCYPFIZER: GOING FORWARD, COMMITTED TO BUILDING CARDIOMETABOLIC PIPELINE, INCLUDING IN OBESITY - PREPARED REMARKSFurther company coverage: PFE.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R71E9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU0225771236.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","LU0170899867.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0058720904.USD","BK4007","BK4533","LU0306806265.USD","LU1023059063.AUD","SG9999011175.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0122379950.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","IE0002270589.USD","SG9999001176.USD","LU0289739699.SGD","LU1883839398.USD","SG9999003800.SGD","BK4599","IE00B19Z3581.USD","BK4550","BK4588","LU0456855351.SGD","PFE","BK4581","SG9999013999.USD","LU1066051498.USD","LU0321505439.SGD","LU1894683348.USD","BK4592","BK4534","LU0306807586.USD","LU1057294990.SGD","SG9999002232.USD","LU0225284248.USD","SG9999001176.SGD"],"gpt_icon":1},{"id":"2531789358","title":"BRIEF-Pfizer Reports First-Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789358?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:12","pubTimestamp":1745925158,"startTime":"0","endTime":"0","summary":"BRIEF-Pfizer Reports First-Quarter 2025 ResultsApril 29 (Reuters) - Pfizer Inc PFE.N:PFIZER Q1 EPS USD 0.52PFIZER Q1 REVENUE USD 13,715 MILLION VERSUS. IBES ESTIMATE USD 13,907 MILLIONPFIZER Q1 NET IN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nPLXE10652:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0225284248.USD","LU0456855351.SGD","LU0306806265.USD","SG9999011175.SGD","IE00BBT3K403.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU0234572021.USD","BK4568","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4588","LU1023059063.AUD","PFE","BK4592","SG9999001176.SGD","LU0321505439.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4599","IE0002270589.USD","BK4533","LU0122379950.USD","IE00B19Z3B42.SGD","SG9999001176.USD","SG9999002224.SGD","LU1057294990.SGD","LU0058720904.USD","BK4534","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4007","IE00BLSP4452.SGD","LU0868494617.USD","LU1066051498.USD","LU0985481810.HKD","LU0321505868.SGD","BK4581"],"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":7,"totalSize":345,"code":"91000000","status":"200"}]}}